Palabras clave
Inmunomodulación
Guías de práctica clínica
Resumen
Las inmunoglobulinas son proteínas heterodiméricas compuestas de 2 cadenas pesadas y 2 cadenas ligeras. La inmunoglobulina G humana es un derivado del plasma y contiene más de 95 % de IgG. La composición de las subclases de IgG es similar a la del plasma humano normal. El tratamiento con inmunoglobulina comenzó hace más de 50 años y su uso se ha descrito en numerosas enfermedades. En Colombia, la importancia de este recurso inmunomodulador condujo a la necesidad de contar con una guía de práctica clínica para su uso, para lo cual se reunió un grupo multidisciplinario de expertos, quienes se distribuyeron en mesas de trabajo, por especialidad, para redactar un texto base. Se llevaron a cabo búsquedas bibliográficas sistemáticas; las evidencias identificadas se valoraron y clasificaron para sustentar un texto preliminar que fue discutido, analizado y corregido. Se emitieron recomendaciones de uso de la inmunoglobulina intravenosa en patologías que abarcan inmunodeficiencias primarias y secundarias, enfermedades autoinmunes, alteraciones neurológicas, infecciones, trasplantes y enfermedades misceláneas; se asignaron calificaciones según el sistema GRADE para cada una. El resultado final se tradujo en las recomendaciones que se presentan con la finalidad de informar, orientar y apoyar en el uso óptimo de dicho recurso inmunomodulador.
Referencias
Schroeder HW, Cavacini L. Structure and function of immunoglobulins. J Allergy Clin Immunol. 2010;125(2 Suppl 2):S41-S52. DOI: http://dx.doi.org/10.1016/ j.jaci.2009.09.046
Berrón R, Espinosa F, Márquez MP, Sainos A, Marfil J, Selva J, et al. Consenso de expertos en el uso terapéutico actual de la inmunoglobulina intravenosa. Rev Alerg Mex. 2005;52(1):42-50. Disponible en: http://edgarluna.info/guias/consenso%20EXPERTO%20INMUNOGLOBULINAS.pdf
Abcam [sitio web]. Antibody structure and isotypes. Guide to the structural components that make up an antibody heavy chains, light chains, F(ab)/Fc regions and isotypes. USA: Abcam; 2017. Disponible en: http://www.abcam.com/protocols/antibody-structure-and-isotypes
Picard C, Al-Herz W, Bousfiha A, Casanova JL, Chatila T, Conley ME, et al. Primary immunodeficiency diseases: An update on the classification from the Internationa Union of Immunologica Societies Expert Committee for Primary Immunodeficiency 2015. J Clin Immunol. 2015;35(8):696-726. DOI:
Cunningham-Rundles C. Key aspects for successful immunoglobulin therapy of primary immunodeficiencies. Clinic Exp Immunol. 2011;164(2):16-19. DOI: http://dx.doi.org/10.1111/j.1365-2249.2011.04390.x
Bonilla FA, Khan DA, Ballas ZK, Chinen J, Frank MM, Hsu JT, et al. Practice parameter for the diagnosis and management of primary immunodeficiency. J Allergy Clin Immunol. 2015;136(5):1186-1205.e1-78. DOI: http://dx.doi.org/10.1016/j.jaci.2015.04.049
Condino-Neto A, Costa-Carvalho BT, Grumach AS, King A, Bezrodnik L, Oleastro M, et al. Guidelines for the use of human immunoglobulin therapy in patients with primary immunodeficiencies in Latin America. Allergol Immunopathol (Madr). 2014;42(3):245-260. DOI: http://dx.doi.org/10.1016/j.aller.2012.09.006
Department of Health and Human Services, Food and Drug Administration; Center for Biologics Evaluation and Research (CBER). Guidance for industry safety, efficacy, and pharmacokinetic studies to support marketing of immune globulin intravenous (Human) as replacement therapy for primary humoral immunodeficiency. US: Department of Health and Human Services, Food and Drug Administration; 2008. Disponible en: http://academy.gmp-compliance.org/guidemgr/files/IGIVIMMUNO.PDF
Orange JS, Grossman WJ, Navickis RJ, Wilkes MM. Impact of trough IgG on pneumonia incidence in primary immunodeficiency: A meta-analysis of clinical studies. Clin Immunol. 2010;137(1):21-30. DOI: http://dx.doi.org/10.1016/j.clim.2010.06.012
Berger M. Principles of and advances in immunoglobulin replacement therapy for primary immunodeficiency. Immunol Allergy Clin North Am. 2008;28(2):413-437. DOI: http://dx.doi.org/10.1016/j.iac.2008.01.008
Winkelstein JA, Marino MC, Lederman HM, Jones SM, Sullivan K, Burks AW, et al. X-linked agammaglobulinemia: Report on a United States registry of 201 patients. Medicine (Baltimore). 2006;85:193-202. DOI: http://dx.doi.org/10.1097/01.md.0000229482.27398.ad
Soresina A, Nacinovich R, Bomba M, Cassani M, Molinaro A, Sciotto A, et al. The quality of life of children and adolescents with X-linked agammaglobulinemia. J Clin Immunol. 2009;29:501-507. DOI: http://dx.doi.org/10.1007/s10875-008-9270-8
Winkelstein JA, Conley ME, James C, Howard V, Boyle J. Adults with X-linked agammaglobulinemia: Impact of disease on daily lives, quality of life, educational and socioeconomic status, knowledge of inheritance, and reproductive attitudes. Medicine (Baltimore). 2008;87:253-258. DOI: http://dx.doi.org/10.1097/MD.0b013e318187ed81
Quartier P, Debré M, De Blic J, de Sauverzac R, Sayegh N, Jabado N, et al. Early and prolonged intravenous immunoglobulin replacement therapy in childhood agammaglobulinemia: A retrospective survey of 31 patients. J Pediatr. 1999;134(5):589-596. DOI: http://dx.doi.org/10.1016/S0022-3476(99)702
Orange JS, Hossny EM, Weiler CR, Ballow M, Berger M, Bonilla FA, et al. Use of intravenous immunoglobulin in human disease: A review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol. 2006;117(4 Suppl):S525-S553. DOI: http://dx.doi.org/10.1016/j.jaci.2006.01.015
Yong PL, Boyle J, Ballow M, Boyle M, Berger M, Bleesing J, et al. Use of intravenous immunoglobulin and adjunctive therapies in the treatment of primary immunodeficiencies: A working group report of and study by the Primary Immunodeficiency Committee of the American Academy of Allergy Asthma and Immunology. Clin Immunol. 2010;135(2):255-263. DOI: http://dx.doi.org/10.1016/j.clim.2009.10.003
Buckley RH. B-cell function in severe combined immunodeficiency after stem cell or gene therapy: A review. J Allergy Clin Immunol. 2010;125(4):790-797. DOI: http://dx.doi.org/10.1016/j.jaci.2010.02.012
Busse PJ, Razvi S, Cunningham-Rundles C. Efficacy of intravenous immunoglobulin in the prevention of pneumonia in patients with common variable immunodeficiency. J Allergy Clin Immunol. 2002;109(6):1001-1004. DOI: http://dx.doi.org/10.1067/mai.2002.124999
Chan WY, Roberts RL, Moore TB, Stiehm ER. Cord blood transplants for SCID: Better b-cell engraftment? J Pediatr Hematol Oncol. 2013;35(1):e14-e18. DOI: http://dx.doi.org/10.1097/MPH.0b013e31824e15b8
Sanal O, Jing H, Ozgur T, Ayvaz D, Strauss-Albee DM, Ersoy-Evans S, et al. Additional diverse findings expand the clinical presentation of DOCK8 deficiency. J Clin Immunol. 2012;32(4):698-708. DOI: http://dx.doi.org/10.1007/s10875-012-9664-5
Zhang Q, Davis JC, Lamborn IT, Freeman AF, Jing H, Favreau AJ, et al. Combined immunodeficiency associated with DOCK8 mutations. N Engl J Med. 2009;361(21):2046-2055. DOI: http://dx.doi.org/10.1056/NEJMoa0905506
Chandesris MO, Melki I, Natividad A, Puel A, Fieschi C, Yun L, et al. Autosomal dominant STAT3 deficiency and hyper-IgE syndrome: Molecular, cellular, and clinical features from a French national survey. Medicine (Baltimore). 2012;91(4):e1-e19. DOI: http://dx.doi.org/10.1097/MD.0b013e31825f95b9
Sowerwine KJ, Holland SM, Freeman AF. Hyper-IgE syndrome update. Ann N Y Acad Sci. 2012;1250:25-32. DOI: http://dx.doi.org/10.1111/j.1749-6632.2011.06387.x
Albert MH, Notarangelo LD, Ochs HD. Clinical spectrum, pathophysiology and treatment of the Wiskott-Aldrich syndrome. Curr Opin Hematol. 2011;18(1):42-48. DOI: http://dx.doi.org/10.1097/MOH.0b013e32834114bc
Albert MH, Bittner TC, Nonoyama S, Notarangelo LD, Burns S, Imai K, et al. X-linked thrombocytopenia (XLT) due to WAS mutations: Clinical characteristics, long-term outcome, and treatment options. Blood. 2010;115(16):3231-3238. DOI: http://dx.doi.org/10.1182/blood-2009-09-239087
López-Granados E, Keenan JE, Kinney MC, Leo H, Jain N, Ma CA, et al. A novel mutation in NFKBIA/IKBA results in a degradation-resistant N-truncated protein and is associated with ectodermal dysplasia with immunodeficiency. Hum Mutat. 2008;29(6):861-868. DOI: http://dx.doi.org/10.1002/humu.20740
Hanson EP, Monaco-Shawver L, Solt LA, Madge LA, Banerjee PP, May MJ, et al. Hypomorphic nuclear factor-kappaB essential modulator mutation database and reconstitution system identifies phenotypic and immunologic diversity. J Allergy Clin Immunol. 2008;122(6):1169.e16-1177.e16. DOI: http://dx.doi.org/10.1016/j.jaci.2008.08.018
Chapel H, Lucas M, Patel S, Lee M, Cunningham-Rundles C, Resnick E, et al. Confirmation and improvement of criteria for clinical phenotyping in common variable immunodeficiency disorders in replicate cohorts. J Allergy Clin Immunol. 2012;130(5):1197-1198.e9. DOI: http://dx.doi.org/10.1016/j.jaci.2012.05.046
Gathmann B, Mahlaoui N, CEREDIH, Gerard L, Oksenhendler E, Warnatz K, et al. Clinical picture and treatment of 2212 patients with common variable immunodeficiency. J Allergy Clin Immunol. 2014;134(1):116-126. DOI: http://dx.doi.org/10.1016/j.jaci.2013.12.1077
Kainulainen L, Vuorinen T, Rantakokko-Jalava K, Osterback R, Ruuskanen O. Recurrent and persistent respiratory tract viral infections in patients with primary hypogammaglobulinemia. J Allergy Clin Immunol. 2010;126(1):120-126. DOI: http://dx.doi.org/10.1016/j.jaci.2010.04.016
Duse M, Iacobini M, Leonardi L, Smacchia P, Antonetti L, Giancane G. Transient hypogammaglobulinemia of infancy: Intravenous immunoglobulin as first line therapy. Int J Immunopathol Pharmacol. 2010;23(1):349-353. DOI: http://dx.doi.org/10.1177/039463201002300134
Bonagura VR. Using intravenous immunoglobulin (IVIG) to treat patients with primary immune deficiency disease. J Clin Immunol. 2013;33 Suppl 2:S90-S94. DOI: http://dx.doi.org/10.1007/s10875-012-9838-1
Memmedova L, Azaris E, Edeer Karacca N, Aksu G, Kutukculer N. Does intravenous immunoglobulin therapy prolong immunodeficiency in transient hypogammaglobulinemia of infancy? Pediatr Resp. 2013;5(3):53-57. DOI: http://dx.doi.org/10.4081/pr.2013.e14
Jurisdictional Blood Committee for and on behalf of the the Australian Health Ministers’ Conference. Criteria for the clinical use of intravenous immunoglobulin in Australia. Second edition. Canberra, Australia: Commonwealth of Australia. 2012. https://www.blood.gov.au/system/files/documents/NBA_IVIgCriteria_SecondEdition_Internals-WEB_updated_ref.pdf
Aittoniemi J, Koskinen S, Laippala P, Laine S, Miettinen A. The significance of IgG subclasses and mannan-binding lectin (MBL) for susceptibility to infection in apparently healthy adults with IgA deficiency. Clin Exp Immunol. 1999;116(3):505-508. DOI: http://dx.doi.org/10.1046/j.1365-2249.1999.00898.x
Wang N, Hammarstrom L. IgA deficiency: What is new? Curr Opin Allergy Clin Immunol. 2012;12(6):602-608. DOI: http://dx.doi.org/10.1097/ACI.0b013e3283594219
Orange JS, Ballow M, Stiehm ER, Ballas ZK, Chinen J, De La Morena M, et al. Use and interpretation of diagnostic vaccination in primary immunodeficiency: A working group report of the Basic and Clinical Immunology Interest Section of the American Academy of Allergy, Asthma & Immunology. J Allergy Clin Immunol. 2012;130(3 Suppl):S1-S24. DOI: http://dx.doi.org/10.1016/j.jaci.2012.07.002
Booth C, Gilmour KC, Veys P, Gennery AR, Slatter MA, Chapel H, et al. X-linked lymphoproliferative disease due to SAP/SH2D1A deficiency: A multicenter study on the manifestations, management and outcome of the disease. Blood. 2011;117(1):53-62. DOI: http://dx.doi.org/10.1182/blood-2010-06-284935
Marsh RA, Madden L, Kitchen BJ, Mody R, McClimon B, Jordan MB, et al. XIAP deficiency: A unique primary immunodeficiency best classified as X-linked familial hemophagocytic lymphohistiocytosis and not as X-linked lymphoproli-ferative disease. Blood. 2010;116(7):1079-1082. DOI: http://dx.doi.org/10.1182/blood-2010-01-256099
Kawai T, Malech HL. WHIM syndrome: Congenital immune deficiency disease. Curr Opin Hematol. 2009;16(1):20-26. DOI: http://dx.doi.org/10.1097/MOH.0b013e32831ac557
Chapel HM, Spickett GP, Ericson D, Engl W, Eibl MM, Bjorkander J, et al. The comparison of the efficacy and safety of intravenous versus subcutaneous immunoglobulin replacement therapy. J Clin Immunol. 2000;20(2):94-100. DOI: http://dx.doi.org/10.1023/A:1006678312925
Berger M. Subcutaneous immunoglobulin replacement in primary immunodeficiencies. Clin Immunol. 2004;112(1):1-7. DOI: http://dx.doi.org/10.1016/j.clim.2004.02.002
Orange JS, Belohradsky BH, Berger M, Borte M, Hagan J, Jolles S, et al. Evaluation of correlation between dose and clinical outcomes in subcutaneous immunoglobulin replacement therapy. Clin Exp Immunol. 2012;169(2):172-181. DOI: http://dx.doi.org/10.1111/j.1365-2249.2012.04594.x
Shapiro R. Subcutaneous immunoglobulin (16 or 20 %) therapy in obese patients with primary immunodeficiency: A retrospective analysis of administration by infusion pump or subcutaneous rapid push. Clin Exp Immunol. 2013;173(2):365-371. DOI: http://dx.doi.org/10.1111/cei.12099
Lingman-Framme J, Fasth A. Subcutaneous immunoglobulin for primary and secondary immunodeficiencies: An evidence-based review. Drugs. 2013;73(12):1307-1319. DOI: http://dx.doi.org/10.1007/s40265-013-0094-3.
Kivity S, Katz U, Daniel N, Nussinovitch U, Papageorgiou N, Shoenfeld Y. Evidence for the use of intravenous immunoglobulins —a review of the literature. Clinic Rev Allerg Immunol. 2010;38(2-3):201-269. DOI: http://dx.doi.org/10.1007/s12016-009-8155-9
Berger M. Principles of and advances in immunoglobulin replacement therapy for primary immunodeficiency. Immunol Allergy Clin North Am. 2008;28(2):413-437. DOI: http://dx.doi.org/10.1016/j.iac.2008.01.008
Shehata N, Palda V, Bowen T, Haddad E, Issekutz TB, Mazer B, et al. The use of immunoglobulin therapy for patients with primary immune deficiency: An evidence-based practice guideline. Transfus Med Rev. 2010;24 Suppl 1:S28-S50. DOI: http://dx.doi.org/10.1016/j.tmrv.2009.09.011
Department of Health. Clinical guidelines for immunoglobulin use: Update to second edition. Unite Kingdom: DH; 2011. Disponible en: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/216671/dh_131107.pdf
Kerr J, Quinti I, Eibl M, Chapel H, Späth PJ, Sewell WA, et al. Is dosing of therapeutic immunoglobulins optimal? A review of a three-decade long debate in Europe. Front Immunol. 2014;5:629. DOI: http://dx.doi.org/10.3389/fimmu.2014.00629
Pierce LR, Jain N. Risks associated with the use of intravenous immunoglobulin. Transfus Med Rev. 2003;17(4):241-251. DOI: http://dx.doi.org/10.1016/S0887-7963(03)00038-5
Song J, Zhang L, Li Y, Quan S, Liang Y, Zeng L, et al. 20% subcutaneous immunoglobulin for patients with primary immunodeficiency diseases: A systematic review. Int Immunopharmacol. 2015;25(2):457-464. DOI: http://dx.doi.org/10.1016/j.intimp.2015.01.016
Sanford M. Human immunoglobulin 10 % with recombinant human hyaluronidase: Replacement therapy in patients with primary immunodeficiency disorders. BioDrugs. 2014;28(4):411-420. DOI: http://dx.doi.org/10.1007/s40259-014-0104-3
Bonilla FA, Duff C. Clinical focus on primary inmunodeficiencies, subcutaneous immunoglobuline replacement. Immune Deficiency Foundation. 2015;16:1-18. Disponible en: http://primaryimmune.org/wp-content/uploads/2015/06/ClinicalFocus_SCIG_2015.pdf
Jolles S, Orange JS, Gardulf A, Stein MR, Shapiro R, Borte M, et al. Current treatment options with immunoglobulin G for the individualization of care in patients with primary immunodeficiency disease. Clin Exp Immunol. 2015;179(2):146-160. DOI: http://dx.doi.org/10.1111/cei.12485
Buehler AM, Flato UP, Ferri CP, Fernandes JG. Is there evidence for recommending specific intravenous immunoglobulin formulations? A systematic review of head-to-head randomized controlled trials. Eur J Pharmacol. 2015;747:96-104. DOI: http://dx.doi.org/10.1016/j.ejphar.2014.11.033
Gouilleux-Gruart V, Chapel H, Chevret S, Lucas M, Malphettes M, Fieschi C, et al. Efficiency of immunoglobulin G replacement therapy in common variable immunodeficiency: Correlations with clinical phenotype and polymorphism of the neonatal Fc receptor. Clin Exp Immunol. 2013;171(2):186-194. DOI: http://dx.doi.org/10.1111/cei.12002
Cunningham-Rundles C. How I treat common variable immune deficiency. Blood. 2010;116(1):7-15. DOI: http://dx.doi.org/10.1182/blood-2010-01-254417
Lucas M, Lee M, Lortan J, Lopez-Granados E, Misbah S, Chapel H. Infection outcomes in patients with common variable immunodeficiency disorders: Relationship to immunoglobulin therapy over 22 years. J Allergy Clin Immunol. 2010;125(6):1354-1360. DOI: http://dx.doi.org/10.1016/j.jaci.2010.02.040
Bayrakci B, Ersoy F, Sanal O, Kiliç S, Metin A, Tezcan I. The efficacy of immunoglobulin replacement therapy in the long-term follow-up of the B-cell deficiencies (XLA, HIM, CVID). Turk J Pediatr. 2005;47(3):239-246.
Galli E, Barbieri C, Cantani A, Solano A, Longhi MA, Businco L. Treatment with gammaglobulin preparation for intravenous use in children with humoral immunodeficiency: Clinical and immunologic follow-up. Ann Allergy. 1990;64(2):147-150.
Cunningham-Rundles C, Siegal FP, Smithwick EM, Lion-Boulé A, Cunningham-Rundles S, O'Malley J, et al. Efficacy of intravenous immunoglobulin in primary humoral immunodeficiency disease. Ann Intern Med. 1984;101(4):435-439. DOI: http://dx.doi.org/10.7326/0003-4819-101-4-435
Agarwal S, Cunningham-Rundles C. Assessment and clinical interpretation of reduced IgG values. Ann Allergy Asthma Immunol. 2007;99(3):281-283. DOI: http://dx.doi.org/10.1016/S1081-1206(10)60665-5
Chapel HM, Lee M, Hargreaves R, Pamphilon DH, Prentice AG. Randomised trial of intravenous immunoglobulin as prophylaxis against infection in plateau-phase multiple myeloma. The UK Group for Immunoglobulin Replacement Therapy in Multiple Myeloma. Lancet. 1994;343(8905):1059-1063.
Raanani P, Gafter-Gvili A, Paul M, Ben-Bassat I, Leibovici L, Shpilberg O. Immunoglobulin prophylaxis in chronic lymphocytic leukemia and multiple myeloma: Systematic review and meta-analysis. Leuk Lymphoma. 2009;50(5):764-772. DOI: http://dx.doi.org/10.1080/10428190902856824
Snowden JA, Ahmedzai SH, Ashcroft J, D'Sa S, Littlewood T, Low E, et al. Guidelines for supportive care in multiple myeloma 2011. Br J Haematol. 2011;154(1):76-103. DOI: http://dx.doi.org/10.1111/j.1365-2141.2011.08574.x
Department of Health. Clinical guidelines for immunoglobulin use: Update to second edition. Scotland (UK): DH; 2011. Disponible en: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/216671/dh_131107.pdf
Guillevin L. Pharmacoeconomics of immunoglobulins and indications for their use. Curr Opin Allergy Clin Immunol. 2013;13 Suppl:S53-S55. DOI: http://dx.doi.org/10.1097/01.all0000433131.08813.66
Friman V, Winqvist O, Blimark C, Langerbeins P, Chapel H, Dhalla F. Secondary immunodeficiency in lymphoproliferative malignancies. Hematol Oncol. 2016;34(3):121-132. DOI: http://dx.doi.org/10.1002/hon.2323
Cooperative Group for the Study of Immunoglobulin in Chronic Lymphocytic Leukemia, Gale RP, Chapel HM, Bunch C, Rai KR, Foon K, et al. Intravenous immunoglobulin for the prevention of infection in chronic lymphocytic leukemia. A randomized, controlled clinical trial. N Engl J Med. 1988;319(14):902-907. DOI: http://dx.doi.org/10.1056/NEJM198810063191403
Dhalla F, Misbah SA. Secondary antibody deficiencies. Curr Opin Allergy Clin Immunol. 2015;15(6):505-513. http://dx.doi.org/10.1097/ACI.0000000000000215
Duraisingham SS, Buckland MS, Grigoriadou S, Longhurst HJ. Secondary antibody deficiency. Expert Rev Clin Immunol. 2014;10(5):583-591. DOI: http://dx.doi.org/10.1586/1744666X.2014.902314
Braamskamp MJ, Dolman KM, Tabbers MM. Clinical practice protein-losing enteropathy in children. Eur J Pediatr. 2010;169(10):1179-1185. DOI: http://dx.doi.org/10.1007/s00431-010-1235-2
Rose ME, Lang DM. Evaluating and managing hypogammaglobulinemia. Cleve Clin J Med. 2006;73(2):133-137,140,143-144.
Vignes S, Bellanger J. Primary intestinal lymphangiectasia (Waldmann’s disease). Orphanet J Rare Dis. 2008;3:5. DOI: http://dx.doi.org/10.1186/1750-1172-3-5
Dierselhuis MP, Boelens JJ, Versteegh FG, Weemaes C, Wulffraat NM. Recurrent and opportunistic infections in children with primary intestinal lymphangiectasia. J Pediatr Gastroenterol Nutr. 2007;44(3):382-385. DOI: http://dx.doi.org/10.1097/01.mpg.0000233192.77521.2f
Alfano V, Tritto G, Alfonsi L, Cella A, Pasanisi F, Contaldo F. Stable reversal of pathologic signs of primitive intestinal lymphangiectasia with a hypolipidic, MCT-enriched diet. Nutrition. 2000;16(4):303-304. DOI: http://dx.doi.org/10.1016/S0899-9007(00)00223-9
De Giacomo C, Maggiore G, Scotta MS, Ugazio AG. Administration of intravenous immunoglobulin in two children with hypogammaglobulinaemia due to protein losing enteropathy. Clin Exp Immunol. 1985;60(2):447-448. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1577039/pdf/clinexpimmunol00134-0225.pdf
Ogi M, Yokoyama H, Tomosugi N, Hisada Y, Ohta S, Takaeda M, et al. Risk factors for infection and immunoglobulin replacement therapy in adult nephrotic syndrome. Am J Kidney Dis. 1994;24(3):427-436.
Dang X, Yi Z, Wang X, Wu X, Zhang X, He Q. Preventive efficiency of IVIgG on nosocomial infection in the children with nephrotic syndrome. Hunan Yi Ke Da Xue Xue Bao. 1999;24(3):290-292.
Nair SK, Petko M, Hayward MP. Aetiology and management of chylothorax in adults. Eur J Cardiothorac Surg. 2007;32(2):362-369. DOI: http://dx.doi.org/10.1016/j.ejcts.2007.04.024
McGrath EE, Blades Z, Anderson PB. Chylothorax: Aetiology, diagnosis and therapeutic options. Respir Med. 2010;104(1):1-8. DOI: http://dx.doi.org/10.1016/j.rmed.2009.08.010
Orange JS, Geha RS, Bonilla FA. Acute chylothorax in children: Selective retention of memory T cells and natural killer cells. J Pediatr. 2003;143(2):243-249. DOI: http://dx.doi.org/10.1067/S0022-3476(03)00305-6
Wasmuth-Pietzuch A, Hansmann M, Bartmann P, Heep A. Congenital chylothorax: Lymphopenia and high risk of neonatal infections. Acta Paediatr. 2004;93(2):220-224. DOI: http://dx.doi.org/10.1111/j.1651-2227.2004.tb00710.x
Hoskote AU, Ramaiah RN, Cale CM, Hartley JC, Brown KL. Role of immunoglobulin supplementation for secondary immunodeficiency associated with chylothorax after pediatric cardiothoracic surgery. Pediatr Crit Care Med. 2012;13(5):535-541. DOI: http://dx.doi.org/10.1097/PCC.0b013e318241793d
Lyons JM, Davis C, Rieman MT, Kopcha R, Phan H, Greenhalgh D, et al. Prophylactic intravenous immune globulin and polymixin B decrease the incidence of septic episodes and hospital length of stay in severely burned children. J Burn Care Res. 2006;27(6):813-818. DOI: http://dx.doi.org/10.1097/01.BCR.0000245421.54312.36
Munster AM, Moran KT, Thupari J, Allo M, Winchurch RA. Prophylactic intravenous immunoglobulin replacement in high-risk burn patients. J Burn Care Rehabil. 1987;8(5):376-380.
Eom TH, Lee HS, Jang PS, Kim YH. Valproate-induced panhypogammaglobulinemia. Neurol Sci. 2013;34(6):1003-1004. DOI: http://dx.doi.org/10.1007/s10072-012-1153-3
Ozaras N, Goksugur N, Eroglu S, Tabak O, Canbakan B, Ozaras R. Carbamazepine-induced hypogammaglobulinemia. Seizure. 2012;21(3):229-231. DOI: http://dx.doi.org/10.1016/j.seizure.2011.12.013
Ashrafi M, Hosseini SA, Abolmaali S, Biglari M, Azizi R, Farghadan M, et al. Effect of anti-epileptic drugs on serum immunoglobulin levels in children. Acta Neurol Belg. 2010;110(1):65-70.
Hayman G, Bansal A. Antibody deficiency associated with carbamazepine. BMJ. 2002;325(7374):1213. DOI: http://dx.doi.org/10.1136/bmj.325.7374.1213
Barmettler S, Price C. Continuing IgG replacement therapy for hypogammaglobulinemia after rituximab-for how long? J Allergy Clin Immunol. 2015;136(5):1407-1409. DOI: http://dx.doi.org/10.1016/j.jaci.2015.06.035
Roberts DM, Jones RB, Smith RM, Alberici F, Kumaratne DS, Burns S, et al. Immunoglobulin G replacement for the treatment of infective complications of rituximab-associated hypogammaglobulinemia in autoimmune disease: A case series. J Autoimmun. 2015;57:24-29. DOI: http://dx.doi.org/10.1016/j.jaut.2014.11.004
Compagno N, Malipiero G, Cinetto F, Agostini C. Immunoglobulin replacement therapy in secondary hypogammaglobulinemia. Front Immunol. 2014;5:626. DOI: http://dx.doi.org/10.3389/fimmu.2014.00626
Roberts DM, Jones RB, Smith RM, Alberici F, Kumaratne DS, Burns S, et al. Rituximab-associated hypogammaglobulinemia: Incidence, predictors and outcomes in patients with multi-system autoimmune disease. J Autoimmun. 2015;57:60-65. DOI: http://dx.doi.org/10.1016/j.jaut.2014.11.009
Kaplan B, Kopyltsova Y, Khokhar A, Lam F, Bonagura V. Rituximab and immune deficiency: Case series and review of the literature. J Allergy Clin Immunol Pract. 2014;2(5):594-600. DOI: http://dx.doi.org/10.1016/j.jaip.2014.06.003
Makatsori M, Kiani-Alikhan S, Manson AL, Verma N, Leandro M, Gurugama NP, et al. Hypogammaglobulinaemia after rituximab treatment-incidence and outcomes. QJM. 2014;107(10):821-828. DOI: http://dx.doi.org/10.1093/qjmed/hcu094
Compagno N, Cinetto F, Semenzato G, Agostini C. Subcutaneous immunoglobulin in lymphoproliferative disorders and rituximab-related secondary hypogammaglobulinemia: A single-center experience in 61 patients. Haematologica. 2014;99(6):1101-1106. DOI: http://dx.doi.org/110.3324/haematol.2013.101261
Besada E, Bader L, Nossent H. Sustained hypogammaglobulinemia under rituximab maintenance therapy could increase the risk for serious infections: A report of two cases. Rheumatol Int. 2013;33(6):1643-1644. DOI: http://dx.doi.org/10.1007/s00296-011-2353-5
National Institute of Child Health and Human Developments Intravenous Immunoglobulin Study Group. Intravenous immune globulin for the prevention of bacterial infections in children with symptomatic human immunodeficiency virus infection. N Engl J Med. 1991;325(2):73-80. DOI: http://dx.doi.org/10.1056/NEJM199107113250201
Huang LC, Myer L, Jaspan HB. The role of polyclonal intravenous immunoglobulin in treating HIV-infected children with severe bacterial infections: A retrospective cohort study. BMC Infect Dis. 2008;8:127. DOI: http://dx.doi.org/10.1186/1471-2334-8-127
Siberry GK, Abzug MJ, Nachman S; Panel on Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Guidelines for the Prevention and Treatment of Opportunistic Infections Among HIV-Exposed and HIV-Infected Children. Pediatr Infect Dis J. 2013;32(12):1303-1307. DOI: http://dx.doi.org/10.1097/INF.0000000000000080
Pastori D, Esposito A, Mezzaroma I. Immunomodulatory effects of intravenous immunoglobulins (IVIGs) in HIV-1 disease: A systematic review. Int Rev Immunol. 2011;30(1):44-66. DOI: http://dx.doi.org/10.3109/08830185.2010.529975
Gvirtzman C, Demirdjian G, Calle G. Gammaglobulina: su uso pediátrico basado en la evidencia científica. Boletín CIME. 2006;9(38). Disponible en: http://www.garrahan.gov.ar/PDFS/cime/octubre06.pdf
Sun C, Tian X, Lee YS, Gunti S, Lipsky A, Herman SE, et al. Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinib. Blood. 2015;126(19):2213-2219. DOI: http://dx.doi.org/10.1182/blood-2015-04-639203
Cabanillas F, Liboy I, Pavia O, Rivera E. High incidence of non-neutropenic infections induced byrituximab plus fludarabine and associated with hypogammaglobulinemia: A frequently unrecognized and easily treatable complication. Ann Oncol. 2006;17(9):1424-1427. DOI: http://dx.doi.org/110.1093/annonc/mdl141
Venhoff N, Effelsberg NM, Salzer U, Warnatz K, Peter HH, Lebrecht D, et al. Impact of rituximab on immunoglobulin concentrations and B cell numbers after cyclophosphamide treatment in patients with ANCA-associated vasculitides. PLoSOne. 2012;7(5):e37626. DOI: http://dx.doi.org/10.1371/journal.pone.0037626
Berlana D, Vidaller A, Jódar R, Fort E, Domingo A, Pastó L. Changes in biochemical, hematological and immunological profiles after low-dose intravenous immunoglobulin administration in patients with hypogammaglobulinemia. Transfus Clin Biol. 2005;12(6):433-440. DOI: http://dx.doi.org/10.1016/j.tracli.2006.02.023
Mulhearn B, Bruce IN. Indications for IGIV in rheumatic diseases. Rheumatology (Oxford). 2015;54(3):383-391. DOI: http://dx.doi.org/10.1093/rheumatology/keu429
Sociedad Española de Farmacia Hospitalaria. Guía clínica para el uso de inmunoglobulinas. Segunda edición. GEMEH; 2011. Disponible en: https://www.sefh.es/bibliotecavirtual/Guia_Igb/Guia_Imnunoglobulinas.pdf
Merrill JT. Treatment of systemic lupus erythematosus: A 2012 update. Bull NYU Hosp Jt Dis. 2012;70(3):172-176. Disponible en: http://hjdbulletin.org/files/archive/pdfs/161.pdf
Nam JL, Ramiro S, Gaujoux-Viala C, Takase K, Leon-Garcia M, Emery P, et al. Efficacy of biological disease-modifying antirheumatic drugs: A systematic literature review informing the 2013 update of the EULAR Recommendations for the management of rheumatoid arthritis. Ann Rheum Dis. 2014;73(3):516-528. DOI: http://dx.doi.org/10.1136/annrheumdis-2013-204577
Ringold S, Weiss PF, Beukelman T, DeWitt EM, Ilowite NT, Kimura Y, et al. 2013 Update of the 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: Recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening among children receiving biologic medications. Arthritis Rheum. 2013;65(10)2499-2512. DOI: http://dx.doi.org/10.1002/art.38092
Katz-Agranov N, Khattri S, Zandman-Goddard G. The role of intravenous immunoglobulins in the treatment of rheumatoid arthritis. Autoimmun Rev. 2015;14(8):651-658. DOI: http://dx.doi.org/10.1016/j.autrev.2015.04.003
Specialised Commissioning Team, NHS England. Clinical Commissioning Policy Statement: Biologic therapies for treatment of Juvenile Idiopathic arthritis (JIA). NHS ENGLAND; 2015. Disponible en: https://www.england.nhs.uk/commissioning/wp-content/uploads/sites/12/2015/10/e03pd-bio-therapies-jia-oct15.pdf
Luqmani RA. State of art in the treatment of systemic vasculitis. Front Immunol. 2104;5:471. DOI: http://dx.doi.org/10.3389/fimmu.2014.00471
Villa-Forte A; European League Against Rheumatism; European Vasculitis Study Group. European League Against Rheumatism/European Vasculitis Study Group recommendations for the management of vasculitis. Curr Opin Rheumatol. 2010;22(1):49-53. DOI: http://dx.doi.org/10.1097/BOR.0b013e328332c9d1
Chen JY, Mao JH. Henoch-Schönlein purpura nephritis in children: Incidence, pathogenesis and management. World J Pediatr. 2015;11(1):29-34. DOI: http://dx.doi.org/10.1007/s12519-014-0534-5
Boom V, Anton J, Lahdenne P, Quartier P, Ravelli A, Wulffraat NM, et al. Evidence-based diagnosis and treatment of macrophage activation syndrome in systemic juvenile idiopathic arthritis. Pediatr Rheumatol Online J. 2015;13:55. DOI: http://dx.doi.org/10.1186/s12969-015-0055-3
Hughes RA, Wijdicks EF, Barohn R, Benson E, Cornblath DR, Hahn AF, et al. Practice parameter: Immunotherapy for Guillain–Barré syndrome. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2003;61(6):736-740. Disponible en: http://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.546.1085&rep=rep1&type=pdf
Hughes RA, Swan AV, van Doorn PA. Intravenous immunoglobulin for Guillain-Barré syndrome. Cochrane Database Syst Rev. 2014;(9):CD002063. DOI: http://dx.doi.org/10.1002/14651858.CD002063.pub6
Elovaara I, Apostolski S, van Doorn P, Gilhus NE, Hietaharju A, Honkaniemi J, et al. EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases: EFNS task force on the use of intravenous immunoglobulin in treatment of neurological diseases. Eur J Neurol. 2008;15(9):893-908. DOI: http://dx.doi.org/10.1111/j.1468-1331.2008.02246.x
Morillo LE, Díaz-Cabezas R, Gutiérrez-Álvarez Am, Lorenzana-Pombo P, Pérez-Romero GE, Rodríguez-Quintana JH, et al. Consenso colombiano sobre la utilidad de la inmunoglobulina intravenosa (IgIV) en enfermedades del sistema nervioso central y periférico. Acta Neurol Colomb. 2007;23(S1:1):S1-S15. Disponible en: http://www.imbiomed.com.mx/1/1/articulos.php?method=showDetail&id_articulo=44619&id_seccion=2839&id_ejemplar=4526&id_revista=122
Figueredo A, Altamirano L, Amores M, Bertoti A, Cueto A, Díaz L, et al. Inmunoglobulina endovenosa en enfermedades neuromusculares: guía para su utilización grupo de trabajo de enfermedades del sistema nervioso periférico de la sociedad neurológica argentina. Rev Neurol Arg. 2006;31(1):32-46. Disponible en: http://www.imbiomed.com.mx/1/1/articulos.php?method=showDetail&id_articulo=5081&id_seccion=2591&id_ejemplar=3887&id_revista=95
Ruts L, Drenthen J, Jacobs BC, van Doorn PA; Dutch GBS Study Group. Distinguishing acute-onset CIDP from fluctuating Guillain-Barre syndrome: A prospective study. Neurology. 2010;74(21):1680-1686. DOI: http://dx.doi.org/10.1212/WNL.0b013e3181e07d14
Dimachkie MM, Saperstein DS. Acquired immune demyelinating neuropathies. Continuum (Minneap Minn). 2014;20(5):1241-1260. DOI: http://dx.doi.org/10.1212/01.CON.0000455883.91426.12
CENETEC. Guía de práctica clínica: Diagnóstico y tratamiento del síndrome de Guillain-Barré en el segundo y tercer nivel de atención. Ciudad de México: Secretaría de Salud; 2016. Disponible en: http://www.cenetec.salud.gob.mx/descargas/gpc/CatalogoMaestro/089_GPC_SxGBarre2y3NA/GuillainBarrE_EVR_CENETEC.pdf
Patwa HS, Chaudhry V, Katzberg H, Rae-Grant AD, So YT. Evidence-based guideline: Intravenous immunoglobulin in the treatment of neuromuscular disorders: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2012;78(13):1009-1015. DOI: http://dx.doi.org/10.1212/WNL.0b013e31824de293
van-den-Bergh PY, Hadden RD, Bouche P, Cornblath DR, Hahn A, Illa I, et al. European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society - first revision. Eur J Neurol. 2010;17(3):356-363. DOI: http://dx.doi.org/10.1111/j.1468-1331.2009.02930.x
Hadden RD, Nobile-Orazio E, Sommer C, Hahn AF, Illa I, Morra E, et al. Paraproteinaemic demyelinating neuropathies. En: Gilhus NE, Barnes MP, Brainin M, editores. European handbook of neurological management. Volumen 1. Oxford, UK: Wiley-Blackwell; 2011. p. 351-361.
Dalakas MC, Quarles RH, Farrer RG, Dambrosia J, Soueidan S, Stein DP, et al. A controlled study of intravenous immunoglobulin in demyelinating neuropathy with IgM gammopathy. Ann Neurol. 1996;40(5):792-795. DOI: http://dx.doi.org/10.1002/ana.410400516
Comi G, Roveri L, Swan A, Willison H, Bojar M, Illa I, et al. A randomized controlled trial of intravenous immunoglobulin in IgM paraprotein associated demyelinating neuropathy. J Neurol. 2002;249(10):1370-1377. DOI: http://dx.doi.org/10.1007/s00415-002-0808-z
Mariette X, Chastang C, Clavelou P, Louboutin JP, Leger JM, Brouet JC. A randomised clinical trial comparing interferon-alpha and intravenous immunoglobulin in polyneuropathy associated with monoclonal IgM. The IgM-associated Polyneuropathy Study Group. J Neurol Neurosurg Psychiatry. 1997;63(1):28-34. Disponible en: http://jnnp.bmj.com/content/jnnp/63/1/28.full.pdf
Eftimov F, Winer JB, Vermeulen M, de Haan R, van Schaik IN. Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev. 2013;(12):CD001797. DOI: http://dx.doi.org/10.1002/14651858.CD001797.pub3
Hughes RA, Donofrio P, Bril V, Dalakas MC, Deng C, Hanna K, et al. Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): A randomized placebo-controlled trial. Lancet Neurol. 2008;7(2):136-144. DOI: http://dx.doi.org/10.1016/S1474-4422(07)70329-0
Racosta JM, Sposato LA, Kimpinski K. Subcutaneous versus intravenous immunoglobulin for chronic autoimmune neuropathies: A meta-analysis. Muscle Nerve. 2017;55(6):802-809. DOI: http://dx.doi.org/10.1002/mus.25409
Leussink VI, Hartung HP, Kieseier BC, Stettner M. Subcutaneous immunoglobulins in the treatment of chronic immune-mediated neuropathies. Ther Adv Neurol Disord. 2016;9(4):336-343. DOI: http://dx.doi.org/10.1177/1756285616641583
van-Schaik IN, Leger JM, Nobile-Orazio E, Cornblath DR, Hadden RD, Koski CL, et al. Multifocal motor neuropathy. En: Gilhus NE, Barnes MP, Brainin M, editores. European Handbook of Neurological Management. Volumen 1. United Kingdom: Wiley-Blackwell; 2011. p. 343-350.
Umapathi T, Hughes RA, Nobile-Orazio E, Léger JM. Immunosuppressant and immunomodulatory treatments for multifocal motor neuropathy. Cochrane Database Syst Rev. 2015;(3):CD003217 DOI: http://dx.doi.org/10.1002/14651858.CD003217.pub5
Eftimov F, Van Schaik IN. Immunotherapy of multifocal motor neuropathy. Expert Opin Biol Ther. 2011;11(3):329-342. DOI: http://dx.doi.org/10.1517/14712598.2011.548798
Bascić-Kes V, Kes P, Zavoreo I, Lisak M, Zadro L, Corić L, et al. Guidelines for the use of intravenous immunoglobulin in the treatment of neurologic diseases. Acta Clin Croat. 2012;51(4):673-683.
Lunn MPT, Nobile-Orazio E. Immunotherapy for IgM anti-myelin-associated glycoprotein paraprotein-associated peripheral neuropathies. Cochrane Database Syst Rev. 2006;10:CD002827. DOI: http://dx.doi.org/10.1002/14651858.CD002827.pub4
Rison RA, Beydoun SR. Paraproteinemic neuropathy: A practical review BMC Neurol. 2016;16:13. DOI: http://dx.doi.org/10.1186/s12883-016-0532-4
Vitaliti G, Tabatabaie O, Matin N, Ledda C, Pavone P, Lubrano R, et al. The usefulness of immunotherapy in pediatric neurodegenerative disorders: A systematic review of literature data. Hum Vaccin Immunother. 2015;11(12):2749-2763. DOI: http://dx.doi.org/10.1080/21645515.2015.1061161
Straussberg R, Schonfeld T, Weitz R, Karmazyn B, Harel L. Improvement of atypical acute disseminated encephalomyelitis with steroids and intravenous immunoglobulins. Pediatr Neurol. 2001;24(2):139-143. DOI: http://dx.doi.org/10.1016/S0887-8994(00)00229-0
Nishikawa M, Ichiyama T, Hayashi T, Ouchi K, Furukawa S. Intravenous immunoglobulin therapy in acute disseminated encephalomyelitis. Pediatr Neurol. 1999;21(2):583-586. DOI: http://dx.doi.org/10.1016/S0887-8994(99)00042-9
Rodríguez-Fernández C, López-Marín L, López-Pino MÁ. Gutiérrez-Solana LG, Soto-Insuga V, Cornejo-Moreno D. Análisis de una serie de casos con diagnóstico inicial de encefalomielitis aguda diseminada en el período 2000-2010. Rev Neurol. 2013;57(7):297-305. Disponible en: https://www.neurologia.com/articulo/2013194
Erol I, Ozkale y, Alkan O, Alehan F. Acute disseminated encephalomyelitis in child and adolescents: A single center experience. Pediatr Neurol. 2013;49(4):266-273. DOI: http://dx.doi.org/10.1016/j.pediatrneurol.2013.03.021
Esposito S, Di Pietro GM, Madini B, Mastrolia MV, Rigante D. A spectrum of inflammation and demyelination in acute disseminated encephalomyelitis (ADEM) of children. Autoimmun Rev. 2015;14(10):923-929. DOI: http://dx.doi.org/10.1016/j.autrev.2015.06.002
Viswanathan S, Wong AH, Quek AM, Yuki N. Intravenous immunoglobulin may reduce relapse frequency in neuromyelitis optica. J Neuroimmunol. 2015;282:92-96. DOI: http://dx.doi.org/10.1016/j.jneuroim.2015.03.021
Elsone L, Panicker J, Mutch K, Boggild M, Appleton R, Jacob A. Role of intravenous immunoglobulin in the treatment of acute relapses of neuromyelitis optica: Experience in 10 patients. Mult Scler. 2014;20(4):501-504. DOI: http://dx.doi.org/10.1177/1352458513495938
Veneselli E, Conte M, Biacncheri R, Acquaviva A, De Bernardini B. Effect of steroid and high-dose immunoglobulin therapy on opsoclonus-myoclonus syndrome occurring in neuroblastoma. Med Pediatr Oncol 1998;30:15-17.
Sugie H, Sugie Y, Akimoto H, Endo K, Shirai M, Ito M. High-dose i.v. human immunoglobulin in a case with infantile opsoclonus polymyoclonia syndrome. Acta Paediatr. 1992;81:371-372. DOI: http://dx.doi.org/10.1111/j.1651-2227.1992.tb12248.x
Leen WG, Weemaes CM, Verbeek MM, Willemsen MA, Rotteveet JJ. Rituximab and intravenous Immunoglobulins for relapsing postinfectious opsoclonus-myoclonus syndrome. Pediatr Neurol. 2008;39(3):213-217. DOI: http://dx.doi.org/10.1016/j.pediatrneurol.2008.05.015
Tate ED, Allison TJ, Pranzantelli MR, Verhulst SJ. Neuroepidemiologic Trends in 105 US Cases of Pediatric Opsoclonus-Myoclonus Syndrome. J Pediatr Oncol Nurs. 2005;22(1):8-19. DOI: http://dx.doi.org/10.1177/1043454204272560
Dalakas MC. The role of IVIg in the treatment of patients with stiff person syndrome and other neurological diseases associated with anti-GAD antibodies. J Neurol. 2005;252(S1):119-125. DOI: http://dx.doi.org/10.1007/s00415-005-1105-4
Dalakas MC, Fujii M, Li M, Lutfi B, Kyhos J, Mcelroy B. High-dose intravenous immune globulin for stiff-person syndrome. N Engl J Med. 2001;345(26):1870-1876. DOI: http://dx.doi.org/10.1056/NEJMoa01167
Živković S. Intravenous immunoglobulin in the treatment of neurologic disorders. Acta Neurol Scand. 2016;133(2):84-96. DOI: http://dx.doi.org/10.1111/ane.12444
Bataller L, Kleopa KA, Wu GF, Rossi JE, Rosenfeld MR, Dalmau J. Autoimmune limbic encephalitis in 39 patients: Immunophenotypes and outcomes. J Neurol Neurosurg Psychiatry. 2007;78(4):381-385. DOI: http://dx.doi.org/10.1136/jnnp.2006.100644
Armangue T, Petit-Pedrol M, Dalmau J. Autoimmune encephalitis in children. J Child Neurol. 2012;27(11):1460-1469. DOI: http://dx.doi.org/10.1177/0883073812448838
Leypoldt F, Armangue T, Dalmau J. Autoimmune encephalopathies. Ann N Y Acad Sci. 2015;1338:94-114. DOI: http://dx.doi.org/10.1111/nyas.12553
Gajdos P, Chevret S, Clair B, Tranchant C, Chastang C. Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Myasthenia Gravis Clinical Study Group. Ann Neurol. 1997;41:789-796. DOI: http://dx.doi.org/10.1002/ana.410410615
Ronager J, Ravnborg M, Hermansen I, Vorstrup S. Immunoglobulin treatment versus plasma exchange in patients with chronic moderate to severe myasthenia gravis. Artif Organs. 2001;25(12):967-973. DOI: http://dx.doi.org/10.1046/j.1525-1594.2001.06717.x
Gajdos P, Chevret S, Toyka KV. Intravenous immunoglobulin for myasthenia gravis. Cochrane Database Syst Rev. 2012;12:CD002277. DOI: http://dx.doi.org/10.1002/14651858.CD002277.pub4
CENETEC. Guía de práctica clínica tratamiento de la miastenia gravis en el adulto. México: Secretaría de Salud; 2010. Disponible en: http://www.cenetec.salud.gob.mx/descargas/gpc/CatalogoMaestro/391_IMSS_10_Miastenia_Gravis/GRR_IMSS_391_10.pdf.
Sorgun MH, Sener HO, Yucesan C, Yucemen N. Intravenous immunoglobulin for prophylaxis of acute exacerbation in myasthenia gravis. Neurol Sci. 2014;35(6):891-96. DOI: http://dx.doi.org/10.1007/s10072-013-1621-4
Achiron A, Barak Y, Miron S, Sarova-Pinhas I. Immunoglobulin treatment in refractory myasthenia gravis. Muscle Nerve. 2000;23(4):551-555.
Hilkevich O, Drory VE, Chapman J, Korczyn AD. The use of intravenous immunoglobulin as maintenance therapy in myasthenia gravis. Clin Neurophamacol. 2001;24(3):173-176.
Arsura EL, Bick A, Brunner NG, Grob D. Effects of repeated doses of intravenous immunoglobulin in myasthenia gravis. Am J Med Sci. 1988;295(5):438-443. DOI: http://dx.doi.org/10.1097/00000441-198805000-00005
Gajdos P, Chevret S. Treatment of myasthenia gravis acute exacerbations with intravenous immunoglobulin. Ann N Y Acad Sci. 2008;1132:271-275. DOI: http://dx.doi.org/10.1196/annals.1405.001
Maddison P, Newsom-Davis J. Treatment for Lambert-Eaton myasthenic syndrome. Cochrane Database Syst Rev. 2005;(2):CD003279. DOI: http://dx.doi.org/10.1002/14651858.CD003279.pub2
Bain PG, Motomura M, Newsom-Davis J, Misbah SA, Chapel HM, Lee ML, et al. Effects of intravenous immunoglobulin on muscle weakness and calcium-channel autoantibodies in the Lambert-Eaton myasthenic syndrome. Neurology. 1996;47(3):678-83.
van-Engelen BG, Renier WO, Weemaes CM, Gabreels FJ, Meinardi H. Immunoglobulin treatment in epilepsy, a review of the literature. Epilepsy Res. 1994;19(3):181-190. DOI: http://dx.doi.org/10.1016/0920-1211(94)90061-2
Türkay S, Baskin E, Dener S, Gültekin A, Tanzer F, Sekreter E. Immune globulin treatment in intractable epilepsy of childhood. Turk J Pediatr. 1996;38(3):301-305.
van-Engelen BG, Renier WO, Weemaes CM. Immunoglobulin treatment in human and experimental epilepsy. J Neurol Neurosurg Psychiatry. 1994;57(S):72-75. DOI: http://dx.doi.org/10.1136/jnnp.57.Suppl.72176
Gross-Tsur V, Shalev RS, Kazir E, Engelhard D, Amir N. Intravenous high-dose gammaglobulins for intractable childhood epilepsy. Acta Neurol Scand. 1993;88(3):204-209. DOI: http://dx.doi.org/10.1111/j.1600-0404.1993.tb04217.x
Spina A, Losito R, Marzocco P, Damato R. Gross-Tsur V, Shalev RS, Kazir E, Engelhard D, Amir N. Treatment of "intractable childhood epilepsy" with high doses of intravenous gamma-globulins. Acta Neurol (Napoli). 1989;11(6):415-422.
Levinson AI. The use of IVIG in neurological disease. Clin Rev Allergy. 1992;10(1-2):119-134.
Etzioni A, Jaffe M, Pollack S, Zelnik N, Benderly A, Tal Y. High dose intravenous gamma-globulin in intractable epilepsy of childhood. Eur J Pediatr. 1991;150(9):681-683.
Britton J. Autoimmune epilepsy. Handb Clin Neurol. 2016;133:219-245. DOI: http://dx.doi.org/10.1016/B978-0-444-63432-0.00013-X
Wong PH, White KM. Impact of Immunoglobulin therapy in pediatric disease: A review of immune mechanisms. Clin Rev Allergy Immunol. 2016;51(3):303-314. DOI: http://dx.doi.org/10.1007/s12016-015-8499-2
Arévalo-Navinés MJ, Aymamí-Soler A, Batlle-Nadal J, Bonaventura-Ibars I, Brieva-Ruiz L, Bufill-Soler E, et al. Guía de práctica clínica sobre la atención a las personas con esclerosis múltiple. España: Departamento de Salud Cataluña; 2012. Disponible en: https://www.cem-cat.org/sites/default/files/guia-practica-clinica.pdf
Gray O, McDonnell GV, Forbes RB. Intravenous immunoglobulins for multiple sclerosis. Cochrane Database Syst Rev. 2003;(4):CD002936. DOI: http://dx.doi.org/10.1002/14651858.CD002936
Clegg A, Bryant J, Milne R. Disease-modifying drugs for multiple sclerosis: A rapid and systematic review. Health Technol Assess. 2000;4(9):1-101. DOI: http://dx.doi.org/10.3310/hta4090
National Institute for Health and Care Excellence. Multiple sclerosis in adults management. United Kingdom; NICE: 2014. Disponible en: https://www.nice.org.uk/guidance/cg186/resources/multiple-sclerosis-in-adults-management-pdf-35109816059077
Goodin DS, Frohman EM, Garmany GP, Halper J, Likosky WH, Lublin FD, et al. Disease modifying therapies in multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology. 2002.58(2):169-178. DOI: http://dx.doi.org/10.1212/WNL.58.2.169
Broadley SA, Barnett MH, Boggild M, Brew BJ, Butzkueven H, Heard R, et al. Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: An Australian and New Zealand perspective. Part 2. New and emerging therapies and their efficacy. MS Neurology Group of the Australian and New Zealand Association of Neurologists. J Clin Neurosci. 2014;21(11):1847-1856. DOI: http://dx.doi.org/10.1016/j.jocn.2014.01.018
Multiple Sclerosis Therapy Consensus Group (MSTCG), Wiendl H, Toyka KV, Rieckmann P, Gold R, Hartung HP, et al. Basic and escalating immunomodulatory treatments in multiple sclerosis: Current therapeutic recommendations. J Neurol. 2008;255(10):1449-1463. DOI: http://dx.doi.org/10.1007/s00415-008-0061-1
Fergusson D, Hutton B, Sharma M, Tinmouth A, Wilson K, Cameron DW, et al. Use of intravenous immunoglobulin for treatment of neurologic conditions: A systematic review. Transfusion. 2005;45(10):1640-1657. DOI: http://dx.doi.org/10.1111/j.1537-2995.2005.00581.x
Rae-Grant A, Rabinstein A, Cree B, Dubinsky R, Day G, Haboubi M, et al. Disease-modifying therapies for multiple sclerosis: A guideline project protocol. Proposal of the guideline development, dissemination, and implementation Subcommittee of the American Academy of Neurology. USA: American Academy of Neurology; 2015. Disponible en: https://www.aan.com/uploadedFiles/Website_Library_Assets/Documents/2.Clinical_Guidelines/3.Browse_By_Status/4.Guidelines_Under_Development/Protocol-Draft-MS-DMT-7-9-15-Final.pdf
Olyaeemanes A, Rahmani M, Goudarzi R, Rahimdel A. Safety and effectiveness assessment of intravenous immunoglobulin in the treatment of relapsing-remitting multiple sclerosis: A meta-analysis. Med J Islam Repub Iran. 2016;30:336. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4898867/pdf/mjiri-30-336.pdf
Sorenson PS, Fazekas F, Lee M. Intravenous immunoglobulin G for the treatment of relapsing-remitting multiple sclerosis: A meta-analysis. Eur J Neurol. 2002;9(6):557-563.
Bien CG, Granata T, Antozzi C, Cross JH, Dulac O, Kurthen M, et al. Pathogenesis, diagnosis and treatment of Rasmussen encephalitis: A European Consensus Statement. Brain. 2005;128(3):454-571. DOI: http://dx.doi.org/10.1093/brain/awh415
Owolabi M. Rasmussen’s encephalitis: An Overview. 2011. En: Hayasaka D, editor. Pathogenesis of encephalitis. USA: InTech. 2011:235-254. DOI: http://dx.doi.org/10.5772/20599
Sheybani L, Schaller K, Seeck M. Rasmussen’s encephalitis: An update. Schweizer Archiv für Neurologie und Psychiatrie. 2011;162(6):225-231. Disponible en: https://pdfs.semanticscholar.org/adac/2a4e7f00df0afc057ee5920d5db88ef3d41d.pdf
Bien C, Schramm J. Treatment of Rasmussen encephalitis half a century after its initial description: Promising prospects and a dilemma. Epilepsy Res. 2009;86(2-3):101-112. DOI: http://dx.doi.org/10.1016/j.eplepsyres.2009.06.001
Nosadini M, Mohammad SS, Suppiej A, Sartori S, Dale RC; IVIG in Neurology Study Group. Intravenous immunoglobulin in paediatric neurology: Safety, adherence to guidelines, and long-term outcome. Dev Med Child Neurol. 2016;58(11):1180-1192. DOI: http://dx.doi.org/10.1111/dmcn.13159
Segal BM. Neurosarcoidosis: Diagnostic approaches and therapeutic strategies. Curr Opin Neurol. 2013;26(3):307-313. DOI: http://dx.doi.org/10.1097/WCO.0b013e3283608459
Ohyama K, Koike H, Takahashi M, Kawagashira Y, Iijima M, Watanabe H, et al. Immunoglobulin G4-related pathologic features in inflammatory neuropathies. Neurology. 2015;85(16):1400-1407. DOI: http://dx.doi.org/10.1212/WNL.0000000000002039
Pagnoux C, Hajj-Ali RA. Pharmacological approaches to CNS vasculitis: Where are we at now? Expert Rev Clin Pharmacol. 2016;9(1):109-116. DOI: http://dx.doi.org/10.1586/17512433.2016.1112265
Ljungman P, Cordonnier C, Einsele H, Bender-Götze C, Bosi A, Dekker A, et al. Use of intravenous immune globulin in addition to antiviral therapy in the treatment of CMV gastrointestinal disease in allogeneic bone marrow transplant patients: A report from the European Group for Blood and Marrow Transplantation (EBMT). Infectious Diseases Working Party of the EBMT. Bone Marrow Transplant. 1998;21(5):473-476. DOI: http://dx.doi.org/10.1038/sj.bmt.1701113
Bhat V, Joshi A, Sarode R, Chavan P. Cytomegalovirus infection in the bone marrow transplant patient. World J Transplant. 2015;5(4):287-291. DOI: http://dx.doi.org/10.5500/wjt.v5.i4.287
Sokos DR, Berger M, Lazarus HM. Intravenous immunoglobulin: Appropriate indications and uses in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2002;8(3):117-130. DOI: http://dx.doi.org/10.1053/bbmt.2002.v8.pm11939601
Emery V, Zuckerman M, Jackson G, Aitken C, Osman H, Pagliuca A, et al. Management of cytomegalovirus infection in haemopoietic stem cell transplantation. Br J Haematol. 2013;162(1):25-39. DOI: http://dx.doi.org/10.1111/bjh.12363
Machado CM, Dulley FL, Boas LS, Castelli JB, Macedo MC, Silva RL, et al. CMV pneumonia in allogeneic BMT recipients undergoing early treatment of pre-emptive ganciclovir therapy. Bone Marrow Transplant. 2000;26:413-417. DOI: http://dx.doi.org/10.1038/sj.bmt.1702526
Torre-Cisneros J, Aguado JM, Caston JJ, Almenar L, Alonso A, Cantisán S, et al. Management of cytomegalovirus infection in solid organ transplant recipients: SET/GESITRA-SEIMC/REIPI recommendations. Transplant Rev (Orlando). 2016:30(3):119-143. DOI: http://dx.doi.org/10.1016/j.trre.2016.04.001
Carbone J. The immunology of post-transplant CMV infection: Potential effect of CMV immunoglobulins on distinct components of the immune response to CMV. Transplantation. 2016;100 Suppl 3:S11-S18. DOI: http://dx.doi.org/10.1097/TP.0000000000001095
Schulz U, Solidoro P, Müller V, Szabo A, Gottlieb J, Wilkens H, et al. CMV immunoglobulins for the treatment of CMV infections in thoracic transplant recipients. Transplantation. 2016;100 Suppl 3:S5-S10. DOI: http://dx.doi.org/10.1097/TP.0000000000001097
Rea F, Potena L, Yonan N, Wagner F, Calabrese F. Cytomegalovirus hyper immunoglobulin for CMV prophylaxis in thoracic transplantation. Transplantation. 2016;100 Suppl 3:S19-S26. DOI: http://dx.doi.org/10.1097/TP.0000000000001096
Grossi P, Mohacsi P, Szabolcs Z, Potena L. Cytomegalovirus Immunoglobulin after thoracic transplantation: An overview. Transplantation. 2016;100 Suppl 3:S1-S4. DOI: http://dx.doi.org/10.1097/TP.0000000000001094
Kotton CN, Kumar D, Caliendo AM, Asberg A, Chou S, Danziger-Isakov L, et al. Updated international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. Transplantation 2013;96(4):333-360. DOI: http://dx.doi.org/10.1097/TP.0b013e31829df29d
Teutsch K, Schweitzer F, Knops E, Kaiser R, Pfister H, Verheyen J, et al. Early identification of renal transplant recipients with high risk of polyomavirus-associated nephropathy. Med Microbiol Immunol. 2015;204(6):657-664. DOI: http://dx.doi.org/10.1007/s00430-015-0398-x
Kuypers DR. Management of polyomavirus-associated nephropathy in renal transplant recipients. Nat Rev Nephrol. 2012;8(7):390-402. DOI: http://dx.doi.org/10.1038/nrneph.2012.64
Johnston O, Jaswal D, Gill JS, Doucette S, Fergusson DA, Knoll GA. Treatment of polyomavirus infection in kidney transplant recipients: A systematic review. Transplantation. 2010;89(9):1057-1070. DOI: http://dx.doi.org/10.1097/TP.0b013e3181d0e15e
Anyaegbu EI, Almond PS, Milligan T, Allen WR, Gharaybeh S, Al-Akash SI. Intravenous immunoglobulin therapy in the treatment of BK viremia and nephropathy in pediatric renal transplant recipients. Pediatr Transplant. 2012:16(1):E19-E24. DOI: http://dx.doi.org/10.1111/j.1399-3046.2010.01384.x
Vu D, Shah T, Ansari J, Naraghi R, Min D. Efficacy of intravenous immunoglobulin in the treatment of persistent BK viremia and BK virus nephropathy in renal transplant recipients. Transplant Proc. 2015;47(2):394-398. DOI: http://dx.doi.org/10.1016/j.transproceed.2015.01.012
Allen U, Alfieri C, Preiksaitis J, Humar A, Moore D, Tapiero B, et al. Epstein-Barr virus infection in transplant recipients: Summary of a workshop on surveillance, prevention and treatment. Can J Infect Dis. 2002;13(2):89-99. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2094856/pdf/JID13089.pdf
San-Juan R, Comoli P, Caillard S, Moulin B, Hirsch HH, Meylan P, et al. Epstein-Barr virus-related post-transplant lymphoproliferative disorder in solid organ transplant recipients. Clin Microbiol Infect. 2014;20 Suppl 7:109-118. DOI: http://dx.doi.org/10.1111/1469-0691.12534
Pastrana DV, Brennan DC, Cuburu N, Storch GA, Viscidi RP, Randhawa PS, et al. Neutralization serotyping of BK polyomavirus infection in kidney transplant recipients. PLoS Pathog. 2012;8(4):e1002650. DOI: http://dx.doi.org/10.1371/journal.ppat.1002650
Sener A, House AA, Jevnikar AM, Boudville N, McAlister VC, Muirhead N, et al. Intravenous immunoglobulin as a treatment for BK virus associated nephropathy: One-year follow-up of renal allograft recipients. Transplantation. 2006;81(1):117-120.
Sharma AP, Moussa M, Casier S, Rehman F, Filler G, Grimmer J, et al. Intravenous immunoglobulin as rescue therapy for BK virus nephropathy. Pediatr Transplant. 2009;13(1):123-129. DOI: http://dx.doi.org/10.1111/j.1399-3046.2008.00958.x
Smith JM, Jordan SC. Intravenous immunoglobulin as treatment for BK virus: Nephropathy. Pediatr Transplant. 2009;13(1):11-13. DOI: http://dx.doi.org/10.1111/j.1399-3046.2008.01105.x
Glotz D, Chapman JR, Dharnidharka VR, Hanto DW, Castro MC, Hirsch HH, et al. The Seville Expert Workshop for Progress in Post-transplant Lymphoproliferative disorders. Transplantation. 2012;94(8):784-793. DOI: http://dx.doi.org/10.1097/TP.0b013e318269e64f
Kekre N, Koreth J. Novel strategies to prevent relapse after allogeneic haematopoietic stem cell transplantation for acute myeloid leukaemia and myelodysplastic syndromes. Curr Opin Hematol. 2015;22:11-22. DOI: http://dx.doi.org/10.1097/MOH.0000000000000116
Cowan J, Cameron DW, Knoll G, Tay J. Protocol for updating a systematic review of randomised controlled trials on the prophylactic use of intravenous immunoglobulin for patients undergoing haematopoietic stem cell transplantation. BMJ Open. 2015;5(8):e008316. DOI: http://dx.doi.org/10.1136/bmjopen-2015-008316
Raanani P, Gafter-Gvili A, Paul M, Ben-Bassat I, Leibovici L, Shpilberg O. Immunoglobulin prophylaxis in hematological malignancies and hematopoietic stem cell transplantation. Cochrane Database Syst Rev. 2008;8(4):CD006501. DOI: http://dx.doi.org/10.1002/14651858.CD006501.pub2
Raanani P, Gafter-Gvili A, Paul M, Ben-Bassat I, Leibovici L, Shpilberg O. Immunoglobulin prophylaxis in hematopoietic stem cell transplantation: systematic review and meta-analysis. J Clin Oncol. 2009;10:770-781. DOI: http://dx.doi.org/10.1200/JCO.2008.16.8450
Tomblyn M, Chiller T, Einsele H, Gress R, Sepkowitz K, Storek J, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: A global perspective. Biol Blood Marrow Transplant. 2009;15(10):1143-238. DOI: http://dx.doi.org/10.1016/j.bbmt.2009.06.019
Sullivan KM, Storek J, Kopecky KJ, Jocom J, Longton G, Flowers M, et al. A controlled trial of long-term administration of intravenous immunoglobulin to prevent late infection and chronic graft vs. host disease after marrow transplantation: Clinical outcome and effect on subsequent immune recovery. Biol Blood Marrow Transplant. 1996;2(1):44-53.
Sullivan KM, Kopecky KJ, Jocom J, Fisher L, Buckner CD, Meyers JD, et al. Immunomodulatory and antimicrobial efficacy of intravenous immunoglobulin in bone marrow transplantation. N Engl J Med. 1990;323(11):702-712. DOI: http://dx.doi.org/10.1056/NEJM199009133231103
Gregoire-Gauthier J, Durrieu J, Duval A, Fontaine F, Dieng MM, Bourgey M, et al. Use of immunoglobulin in the prevention of GvHD in a xenogeneic NOD/SCID/yc- mouse model. Bone Marrow Transplant. 2012;47(3):439-450. DOI: http://dx.doi.org/10.1038/bmt.2011.93
Abdel-Mageed A, Graham-Pole J, Del Rosario ML, Longmate J, Ochoa S, Amylon M, et al. Comparison of two doses of intravenous immunoglobulin after allogeneic bone marrow transplants. Bone Marrow Transplant. 1999;23(9):929-932. DOI: http://dx.doi.org/10.1038/sj.bmt.1701742
Gosset C, Viglietti D, Hue K, Antoine C, Glotz D, Pillebout E. How many times can parvovirus B19-related anemia recur in solid organ transplant recipients?. Transpl Infect Dis. 2012;14(5):E64-E70. DOI: http://dx.doi.org/10.1111/j.1399-3062.2012.00773.x
Eid AJ, Brown RA, Patel R, Razonable RR. Parvovirus B19 infection after transplantation: A review of 98 cases. Clin Infect Dis. 2006;43(1):40-48. DOI: http://dx.doi.org/10.1086/504812
Jordan SC, Toyoda M, Kahwaji J, Vo AA. Clinical aspects of intravenous immunoglobulin use in solid organ transplant recipients. Am J Transplant. 2011;11(2):196-202. DOI: http://dx.doi.org/10.1111/j.1600-6143.2010.03400.x
Eid AJ, Posfay-Barbe KM; AST Infectious Diseases Community of Practice. Parvovirus B19 in solid organ transplant recipients. Am J Transplant. 2009;9 Suppl 4:S147-S150. DOI: http://dx.doi.org/10.1111/j.1600-6143.2009.02905.x
Crabol Y, Terrier B, Rozenberg F, Pestre V, Legendre C, Hermine O, et al. Intravenous immunoglobulin therapy for pure red cell aplasia related to human parvovirus b19 infection: A retrospective study of 10 patients and review of the literature. Clin Infect Dis. 2013;56(7):968-977. DOI: http://dx.doi.org/10.1093/cid/cis1046
Salcedo J, Keates S, Pothoulakis C, Warny M, Castagliuolo I, LaMont JT, et al. Intravenous immunoglobulin therapy for severe Clostridium difficile colitis. Gut. 1997;41(3):366-370. Disponible en: http://gut.bmj.com/content/gutjnl/41/3/366.full.pdf
Abougergi MS, Kwon JH. Intravenous immunoglobulin for the treatment of Clostridium difficile infection: A review. Dig Dis Sci. 2011;56(1):19-26. DOI: http://dx.doi.org/10.1007/s10620-010-1411-2
Abougergi MS, Broor A, Cui W, Jaar BG. Intravenous immunoglobulin for the treatment of severe Clostridium difficile colitis: An observational study and review of the literature. J Hosp Med. 2010;5(1):E1-E9. DOI: http://dx.doi.org/10.1002/jhm.542
Shahani L, Koirala J. Intravenous immunoglobulin in treatment of Clostridium difficile colitis. BMJ Case Rep. 2012. DOI: http://dx.doi.org/10.1136/bcr.10.2011.5052
Department of Health. Clinical guidelines for immunoglobulin use: Update to second edition. United Kingdom: DH; 2011. Disponible en: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/216671/dh_131107.pdf
Shah N, Shaaban H, Spira R, Slim J, Boghossian J. Intravenous immunoglobulin in the treatment of severe Clostridium difficile colitis. J Global Infect Dis. 2014;6(2):82-85. DOI: http://dx.doi.org/10.4103/0974-777X.132053
Shah PJ, Vakil N, Kabakov A. Role of intravenous immune globulin in streptococcal toxic shock syndrome and Clostridium difficile infection. Am J Health Syst Pharm. 2015;72(12):1013-1019. DOI: http://dx.doi.org/10.2146/ajhp140359
Bagdasarian N, Rao K, Malani PN. Diagnosis and treatment of Clostridium difficile in adults: A systematic review. JAMA. 2015;313(4):398-408. DOI: http://dx.doi.org/10.1001/jama.2014.17103R
Sociedad Española de Farmacia Hospitalaria. Guía clínica para el uso de inmunoglobulinas. Segunda edición. España: GEMEH; 2011. Disponible en: https://www.sefh.es/bibliotecavirtual/Guia_Igb/Guia_Imnunoglobulinas.pdf
Furusho K, Kamiya T, Nakano H, Kiyosawa N, Shinomiya K, Hayashidera T, et al. High-dose intravenous gammaglobulin for Kawasaki disease. Lancet. 1984;2(8411):1055-1058. DOI: http://dx.doi.org/10.1016/S0140-6736(84)91504-6
Newburger JW, Takahashi M, Burns JC, Beiser AS, Chung KJ, Duffy CE, et al. The treatment of Kawasaki syndrome with intravenous gamma globulin. N Engl J Med. 1986;315(6):341-347. DOI: http://dx.doi.org/10.1056/NEJM198608073150601
Newburger JW, Takahashi M, Beiser AS, Burns JC, Bastian J, Chung KJ, et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N Engl J Med. 1991;324:1633-1639. DOI: http://dx.doi.org/ 10.1056/NEJM199106063242305
Eleftheriou D, Levin M, Shingadia D, Tulloh R, Klein NJ, Brogan PA. Management of Kawasaki disease. Arch Dis Child. 2014;99(1):74-83. DOI: http://dx.doi.org/10.1136/archdischild-2012-302841
Research Committee of the Japanese Society of Pediatric Cardiology; Cardiac Surgery Committee for Development of Guidelines for Medical Treatment of Acute Kawasaki Disease. Guidelines for medical treatment of acute Kawasaki disease: Report of the Research Committee of the Japanese Society of Pediatric Cardiology and Cardiac Surgery (2012 revised version). Pediatr Int. 2014;56(2):135-158. DOI: http://dx.doi.org/10.1111/ped.12317
Zhu BH, Lv HT, Sun L, Zhang JM, Cao L, Jia HL, et al. A meta-analysis on the effect of corticosteroid therapy in Kawasaki disease. Eur J Pediatr. 2012;171(3):571-578. DOI: http://dx.doi.org/10.1007/s00431-011-1585-4
Newburger JW, Takahashi M, Gerber MA, Gewitz MH, Tani LY, Burns JC, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: A statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Pediatrics. 2004;114(6):1708-1733. DOI: http://dx.doi.org/10.1542/peds.2004-2182
Sundel RP, Burns JC, Baker A, Beiser AS, Newburger JW. Gammaglobulin re-treatment in Kawasaki disease. J Pediatr. 1993;12384):657-659.
Miura M, Ohki H, Tsuchihashi T, Yamagishi H, Katada Y, Yamada K, et al. Coronary risk factors in Kawasaki disease treated with additional gammaglobulin. Arch Dis Child. 2004;89(8):776-780. DOI: http://dx.doi.org/10.1136/adc.2003.032748
Kaul R, McGeer A, Norrby-Teglund A, Kotb M, Schwartz B, O’Rourke K, et al. Intravenous immunoglobulin therapy for streptococcal toxic shock syndrome-a comparative observational study The Canadian Streptococcal Study Group. Clin Infect Dis. 1999;28(4):800-807. DOI: http://dx.doi.org/10.1086/515199
Darenberg J, Ihendyane N, Sjölin J, Aufwerber E, Haidl S, Follin P, et al. Intravenous immunoglobulin G therapy in streptococcal toxic shock syndrome: A European randomized, double-blind, placebo-controlled trial. Clin Infect Dis. 2003;37(3):333-340. DOI: http://dx.doi.org/10.1086/376630
Linnér A, Darenberg J, Sjölin J, Henriques-Normark B, Norrby-Teglund A. Clinical efficacy of polyspecific intravenous immunoglobulin therapy in patients with streptococcal toxic shock syndrome: A comparative observational study. Clin Infect Dis. 2014;59(6):851-857. DOI: http://dx.doi.org/10.1093/cid/ciu449
Shah SS, Hall M, Srivastava R, Subramony A, Levin JE. Intravenous Immune Globulin in Children with Streptococcal Toxic Shock Syndrome. Clin Infect Dis. 2009;49(9):1369-1376. DOI: http://dx.doi.org/10.1086/606048.
Wahn V, Orange J. Clinical use of immunoglobulins. Segunda edición. Alemania: Uni-Med Verlang; 2013. p. 95.
Bermejo-Martín JF, Rodríguez-Fernández A, Herrán-Monge R, Andaluz-Ojeda D, Muriel-Bombín A, Marino P, et al. Immunoglobulins IgG1, IgM and IgA: A synergistic team influencing survival in sepsis. J Intern Med. 2014;276(4):404-412. DOI: http://dx.doi.org/10.1111/joim.12265
Berlot G, Vassallo MC, Busetto N, Bianchi M, Zornada F, Rosato I, et al. Relationship between the timing of administration of IgM and IgA enriched immunoglobulins in patients with severe sepsis and septic shock and the outcome: A retrospective analysis. J Crit Care. 2012;27(2):167-171. DOI: http://dx.doi.org/10.1016/j.jcrc.2011.05.012
Ortega-López MC, Arboleda-Salaiman J. Imunoglobulina endovenosa em pacientes pediátricos e adultos em unidades de terapia intensiva com síndrome de resposta inflamatória sistêmica grave e/ou síndrome de disfunção de múltiplos órgãos. Braz J Allergy Immunol. 2013;1(3):149-154. DOI: http://dx.doi.org/10.5935/2318-5015.20130015
Alejandria MM, Lansang MA, Dans LF, Mantaring JB 3rd. Intravenous immunoglobulin for treating sepsis, severe sepsis and septic shock. Cochrane Database Syst Rev. 2013;(9):CD001090. DOI: http://dx.doi.org/10.1002/14651858.CD001090.pub2
Pildal J, Gotzsche PC. Polyclonal immunoglobulin for treatment of bacterial sepsis: A systematic reviews. Clin Infect Dis. 2004;39(1):38-46. DOI: http://dx.doi.org/10.1086/421089
Ohlsson A, Lacy JB. Intravenous immunoglobulin for preventing infection in preterm and/or low birth weight infants. Cochrane Database Syst Rev. 2013;(7):CD000361. DOI: http://dx.doi.org/10.1002/14651858.CD000361.pub3
Ohlsson A, Lacy JB. Intravenous immunoglobulin for suspected or subsequently proven infection in neonates. Cochrane Database Syst Rev. 2010;(3):CD001239. DOI: http://dx.doi.org/10.1002/14651858.CD001239.pub3
INIS Collaborative Group, Brocklehurst P, Farrell B, King A, Juszczak E, Darlow B, et al. The. Treatment of neonatal sepsis with intravenous immune globulin. New Engl J Med. 2011;365(13):1201-1211. DOI: http://dx.doi.org/10.1056/NEJMoa1100441
Beken S, Hirfanoglu I, Turkyilmaz C, Altuntas N, Unal S, Turan, et al. Intravenous immunoglobulin G treatment in ABO hemolytic disease of the Newborn, is it myth or real? Indian J Hematol Blood Transfus. 2014;30(1):12-15. DOI: http://dx.doi.org/10.1007/s12288-012-0186-3
Figueras-Aloy J, Rodríguez-Miguélez JM, Iriondo-Sanz M, Salvia-Roiges MD, Botet-Mussons F, Carbonell-Estrany X. Intravenous immunoglobulin and necrotizing enterocolitis in newborns with hemolytic disease. Pediatrics. 2010;125(1):139-144. DOI: http://dx.doi.org/10.1542/peds.2009-0676
Corvaglia L, Legnani E, Galletti S, Arcuri S, Aceti A, Faldella G. Intravenous immunoglobulin to treat neonatal alloimmune haemolytic disease. J Materm Fetal Neonatal Med. 2012;25(12):2782-2785. DOI: http://dx.doi.org/10.3109/14767058.2012.718387
Bertrand G, Kaplan C. How do we treat fetal and neonatal alloimmune thrombocytopenia? Transfusion. 2014;54(7):1698-1703. DOI: http://dx.doi.org/10.1111/trf.12671
Smits-Wintjens VE, Walther FJ, Rath ME, Lindenburg IT, te Pas AB, Kramer CM, et al. Intravenous immunoglobulin in neonates with rhesus hemolytic disease: A randomized controlled trial. Pediatrics. 2011;127(4):680-686. DOI: http://dx.doi.org/10.1542/peds.2010-3242
Capasso L, Borrelli A, Cerullo J, Pisanti R, Figliuolo C, Izzo F, et al. Role of immunoglobulins in neonatal sepsis. Transl Med UniSa. 2015;11:28-33. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4309652/pdf/tm-11-28.pdf
Shehata N, Palda VA, Meyer RM, Blydt-Hansen TD, Campbell P, Cardella C et al. The use of immunoglobulin therapy for patients undergoing solid organ transplantation: An evidence-based practice guideline. Transfus Med Rev. 2010;24 Suppl 1:S7-S27. DOI: http://dx.doi.org/10.1016/j.tmrv.2009.09.010
Jordan SC, Tyan D, Stablein D, McIntosh M, Rose S, Vo A, et al. Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: Report of the NIH IG02 trial. J Am Soc Nephrol. 2004;15(12):3256-3262. DOI: http://dx.doi.org/10.1097/01.ASN.0000145878.92906.9F
Jordan SC, Vo A, Tyan D, Toyota M. Desensitization therapy with intravenous gammaglobulin (IVIG): Applications in solid organ transplantation. Trans Am Clin Climatol Assoc. 2006;117:199-211. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1500934/pdf/tacca117000199.pdf
Peraldi MN, Akposso K, Haymann JP, Flahaunt A, Marlin C, Rondeau E, et al. Long-term benefit of intravenous immunoglobulins in cadaveric kidney retransplantation. Transplantation. 1996;62(11):1670-1673.
Casadei DH, del C Rial M, Opelz G, Golberg JC, Argento JA, Greco G, et al. A randomized and prospective study comparing treatment with high-dose intravenous immunoglobulin with monoclonal antibodies for rescue of kidney grafts with steroid-resistant rejection. Transplantation. 2001;71(1):53-58.
Dignan FL, Scarisbrick JJ, Cornish J, Clark A, Amrolia P, Jackson G, et al. Organ-specific management and supportive care in chronic graft-versus-host disease. Br J Haematol. 2012;158(1):62-78. DOI: http://dx.doi.org/10.1111/j.1365-2141.2012.09131.x
Winston DJ, Antin JH, Wolff SN, Bierer BE, Small T, Miller KB, et al. A multicenter, randomized, double-blind comparison of different doses of intravenous immunoglobulin for prevention of graft-versus-host disease and infection after allogeneic bone marrow transplantation. Bone Marrow Transplant. 2001;28(2):187-196. DOI: http://dx.doi.org/10.1038/sj.bmt.1703109
Leffell J, Jones RJ, Gladstone DE. Donor HLA-specific Abs: To BMT or not to BMT? Bone Marrow Transplant. 2015,50(6):751-758. DOI: http://dx.doi.org/10.1038/bmt.2014.331
Huang YC, Chien YN, Chen YT, LI YC, Chen TJ. Intravenous immunoglobulin for the treatment of toxic epidermal necrolysis: A systematic review and meta-analysis. G Ital Dermatol Venereol. 2016;151(5):515-524.
Enk A, Hadaschik E, Eming R, Fierlbeck G, French L, Girolomoni G, et al. European Guidelines (S1) on the use of high-dose intravenous immunoglobulin in dermatology. J Dtsch Dermatol Ges. 2016;15(2):228-241. DOI: http://dx.doi.org/10.1111/ddg.13013.
Barron SJ, Del Vecchio MT, Aronoff SC. Intravenous immunoglobulin in the treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis: A meta-analysis with meta-regression of observational studies. Int J Dermatol. 2015;54(1):108-115. DOI: http://dx.doi.org/10.1111/ijd.12423
CENETEC. Guía de referencia rápida. Diagnóstico y tratamiento del síndrome de Stevens-Johnson/necrólisis epidérmica tóxica en el adulto. México: Secretaría de Salud; 2010. Disponible en: http://www.cenetec.salud.gob.mx/descargas/gpc/CatalogoMaestro/398_GPC_Diagnostico_tratamiento_SINDROME_STEVENS_JOHNSON/GRR_STEVENS_JONSON.pdf
Fromowitz JS, Ramos-Caro FA, Flowers FP; University of Florida. Practical guidelines for the management of toxic epidermal necrolysis and Stevens-Johnson syndrome. Int J Dermatol. 2007;46(10):1092-1094. DOI: http://dx.doi.org/10.1111/j.1365-4632.2007.03277.x
Saldarriaga C, Angulo D, Ramírez L, Úsuga Y, Velásquez M. Use of intravenous immunoglobulin in severe pemphigus vulgaris presenting with sepsis: A case series. Poster 47th Annual Meeting of the American Academy of Dermatology, Washington, United States, 2016.
Venning VA, Taghipour K, Mustapa MF, Highet AS, Kirtschig G. British Association of Dermatologists' guidelines for the management of bullous pemphigoid 2012. Br J Dermatol. 2012;167(6):1200-1214. DOI: http://dx.doi.org/10.1111/bjd.12072
Frew J, Martin L, Murrel D. Evidence-based treatments in pemphigus vulgaris and pemphigus foliaceus. Dermatol Clin. 2011;29:599-606. DOI: http://dx.doi.org/10.1016/j.det.2011.07.001
Daniel BS, Borradori L, Hall RP 3rd, Murrell DF. Evidence-based Management of bullous pemphigoid. Dermatol Clin. 2011;29(4):613-620. DOI: http://dx.doi.org/10.1016/j.det.2011.06.003.
Amagai M, Ikeda S, Shimiszu H, Iizuka, H, Hanada K, Aiba S, et al. A randomized double-blind trial of intravenous immunoglobulin for pemphigus. J Am Acad Dermatol. 2009;60(4):595-603. DOI: http://dx.doi.org/10.1016/j.jaad.2008.09.052
Jee SJ, Kim JH, Baek HS, Lee HB, Oh JW. Long Term efficacy on intraglobulin therapy for moderate to severe childhood atopic dermatitis. Allergy Asthma Immunol Res. 2011;3(2):88-95. DOI: http://dx.doi.org/10.4168/aair.2011.3.2.89
Crowe BH, Salt AT. Autism: The management and support of children and young people on the autism spectrum (NICE Clinical Guideline 170). Arch Dis Child Educ Pract Ed. 2015;100(1):20-23. DOI: http://dx.doi.org/10.1136/archdischild-2013-305468
Fuentes-Biggi J, Ferrari-Arroyo MJ, Boada-Muñoz L, Touriño-Aguilera E, Artigas-Pallarés J, Belinchón-Carmona M, et al. Good practice guidelines for the treatment of autistic spectrum disorders. Rev Neurol. 2006;43(7):425-438.
Kovacevic M, Grant P, Swedo SE. Use of intravenous immunoglobulin in the treatment of twelve youths with pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections. J Child Adolesc Psychopharmacol. 2015;25(1):65-69. DOI: http://dx.doi.org/10.1089/cap.2014.0067
Swedo SE, Leonard HL, Rapoport JL. The pediatric autoimmune neuropsychiatric disorders associated with streptococcal infection (PANDAS) subgroup: Separating fact from fiction. Pediatrics. 2004;113(4):907-911.
Vollmer-Conna U, Hickie I, Hadzi-Pavlovic D, Tymms K, Wakefield D, Dwyer J, et al. Intravenous immunoglobulin is ineffective in the treatment of patients with chronic fatigue syndrome. Am J Med. 1997;103(1):38-43. DOI: http://dx.doi.org/10.1016/S0002-9343(97)90045-0
Balfour-Lynn IM, Mohan U, Bush A, Rosenthal M. Intravenous immunoglobulin for cystic fibrosis lung disease: A case series of 16 children. Arch Dis Child. 2004;89(4):315-319. DOI: http://dx.doi.org/10.1136/adc.2003.026575
Ortega-López MC, Escobar-Quintero A, Barrero-Miranda DC. Basal serum levels of immunoglobulins G, A, M, and E in the group of patients with cystic fibrosis at Hospital Infantil Universitario de San José Bogotá DC, in 2014. Alergia e Inmunol Pediatr. 2016;25(2):38-45. Disponible en: http://www.medigraphic.com/pdfs/alergia/al-2016/al162b.pdf
Robinson J, Hartling L, Vandermeer B, Klassen TP. Intravenous immunoglobulin for presumed viral myocarditis in children and adults. Cochrane Database Syst Rev. 2015;(5):CD004370. DOI: http://dx.doi.org/10.1002/14651858.CD004370.pub3
Maisch B, Pankuweit S. Standard and etiology-directed evidence-based therapies in myocarditis: State of the art and future perspectives. Heart Fail Rev. 2013;18(6):761-795. DOI: http://dx.doi.org/10.1007/s10741-012-9362-7
Bhatt GC, Sankar J, Kushwaha KP. Use of intravenous immunoglobulin compared with standard therapy is associated with improved clinical outcomes in children with acute encephalitis syndrome complicated by myocarditis. Pediatr Cardiol. 2012;33(8):1370-1376. DOI: http://dx.doi.org/10.1007/s00246-012-0350-4
Stephenson MD, Kutteh WH, Purkiss S, Librach C, Schultz P, Houlihan E, et al. Intravenous immunoglobulin and idiopathic secondary recurrent miscarriage: A multicentered randomized placebo-controlled trial. Hum Reprod. 2010;25(9):2203-2209. DOI: http://dx.doi.org/10.1093/humrep/deq179
Ata B, Tan SL, Shehata F, Holzer H, Buckett W. A systematic review of intravenous immunoglobulin for treatment of unexplained recurrent miscarriage. Fertil Steril. 2011;95(3):1080-1085. DOI: http://dx.doi.org/10.1016/j.fertnstert.2010.12.021
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial 4.0.
Derechos de autor 2017 Revista Alergia México